CVS-Aetna Merger Costs You Money: The PBM Monopoly Explained

If your insurance company compels you to use a CVS pharmacy, this is why. When CVS acquired Aetna for $77 billion in 2018, it created a healthcare giant that profits from your prescriptions at three different levels—and uses that power to squeeze out competitors and raise your costs. This is part of a broader pattern of insurance industry consolidation driving up healthcare costs.

The $77 Billion Deal

In December 2017, CVS announced it would buy Aetna for $69 billion—the biggest healthcare merger in American history. CVS promised "integrated care" and "lower costs." The reality: higher prices, fewer choices, and one company controlling your prescriptions from start to finish. (Source: CVS Health Press Release, 2017)

By November 2018, the deal closed after the Department of Justice approved it with minimal conditions—requiring only that Aetna divest its Medicare Part D business. The DOJ explicitly declined to address the monopolization concerns that consumer advocates had raised. (Source: DOJ Press Release, October 2018)

Even the federal judge overseeing the merger, Richard Leon, expressed concern. In an unprecedented move, he held public hearings under the Tunney Act to examine whether the settlement protected the public interest. Judge Leon questioned whether the DOJ's remedy addressed "about one-tenth of 1%" of the issues raised. (Source: Reuters, 2018)

Ultimately, he approved the merger anyway.

What Is a Pharmacy Benefit Manager?

A pharmacy benefit manager (PBM) is a company that acts as a middleman between health insurers, drug manufacturers, and pharmacies. PBMs decide which drugs your insurance covers (the "formulary"), negotiate rebates from drug makers, and set reimbursement rates for pharmacies. The three largest PBMs—CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth)—control approximately 80% of U.S. prescriptions. (Source: FTC Interim Report, 2024)

Most Americans have never heard of PBMs. But these companies touch nearly every prescription filled in America—and they operate with remarkably little transparency.

The Three-Way Squeeze: How CVS Profits From Your Prescription Three Times

When CVS acquired Aetna, it created something unprecedented: a single company that controls the insurance (Aetna), the PBM (CVS Caremark), and the pharmacy (CVS stores and Caremark mail-order). Economists call this "vertical integration." In this case it's hurdling toward monopolization.

Here's how CVS profits at each step:

1. The Insurance (Aetna)

Aetna collects your premium and decides your copays, deductibles, and which pharmacies are "preferred."

Guess which pharmacy Aetna prefers?

2. The PBM (CVS Caremark)

CVS Caremark negotiates rebates from drug manufacturers—sometimes 50% or more of a drug's list price. They don't pass those rebates to you. The FTC found PBMs keep significant rebate portions as profit while you pay prices based on inflated list prices. (Source: FTC Interim Report, 2024)

3. The Pharmacy (CVS)

CVS fills your prescription at its own stores—collecting the dispensing fee and markup.

The result: CVS Health takes a cut from your premium, a cut from drug manufacturers, and a cut when you fill. They own all three pieces, so they design the system to maximize profit at your expense.

Senator Markwayne Mullin (R-Okla.) likened PBMs owning pharmacies to "the fox guarding the henhouse." When PBMs claim 98% of rebates go to "customers," health plans—which they also own—are included. "So you're rebating yourselves," Mullin said. (Source: MedPage Today, 2024)

This kind of vertical monopolization isn't new—the government has blocked it before. In 1948, the Supreme Court forced studios like Paramount to sell their theaters. When one company owns production, distribution, and exhibition, competition dies and prices are easily manipulated. The principle was clear: you can't control the whole pipeline.

CVS now owns your insurer, your PBM, and your pharmacy. Same structure. Same problem. But this time, no one stopped them.

The Evidence: What Regulators Have Found

As Senator Bernie Sanders put it: "Let's be clear, while Americans pay outrageously high prices for prescription drugs, the pharmaceutical companies and the PBMs make enormous profits every year." (Source: MedPage Today, 2024)

FTC Investigation Reveals "Hundreds or Thousands of Percent" Markups

In 2024 and 2025, the Federal Trade Commission released a series of interim reports based on a comprehensive investigation into PBM practices. The findings were damning.

The FTC found that the three largest PBMs—CVS's Caremark Rx, Express Scripts, and OptumRx—generated $7.3 billion in excess revenue from specialty generic drug markups between 2017 and 2022. These markups ranged from "hundreds or even thousands of percent" above what the PBMs paid to acquire the drugs. (Source: FTC Report on Specialty Drug Markups, 2025)

In plain language: CVS Caremark and its competitors were buying generic drugs cheaply and selling them to patients and insurers at massively inflated prices—while pocketing the difference. This contributes to the estimated $88 billion Americans lose annually to medical billing errors.

House Judiciary Committee: "When CVS Writes the Rules"

In January 2026, the House Judiciary Committee released a scathing report titled "When CVS Writes the Rules: How CVS Protects Itself From Innovation and Competition." The report was based on over 2,200 internal CVS documents obtained through subpoena. (Source: House Judiciary Committee Report, January 2026)

Key findings included:

• Cease-and-desist campaigns: CVS sent cease-and-desist letters to independent pharmacies that partnered with "pharmacy hub" services trying to help patients access specialty medications at lower costs
• Exclusionary contracts: CVS Caremark used contract terms that effectively locked patients into CVS pharmacies
• Spread pricing: CVS Caremark charged health plans more for drugs than it paid pharmacies, pocketing the "spread"

The committee concluded that CVS "may have violated federal antitrust laws" and referred its findings to the Department of Justice and FTC.

Real-World Impact: What This Means for You

Your Pharmacy Is Disappearing

Between 2010 and 2021, 29.4% of retail pharmacies in the United States closed. Independent pharmacies closed at twice the rate of chain pharmacies. (Source: Health Affairs, 2024)

Why are pharmacies closing? The economics have become impossible. PBMs set reimbursement rates so low that many independent pharmacies lose money on prescriptions—even as the PBMs' own pharmacies thrive.

This isn't competition. It's a monopoly eliminating rivals.

Competitors Get Crushed

USC and NBER researchers found that insurers without their own PBMs saw premiums rise 36% as monopolization increased in the market. The monopolies aren't just profiting—they're using market power to destroy competitors. (Source: USC Schaeffer Center, 2023)

"Steering" Patients to CVS

When Aetna designs your insurance plan to require you to fill prescriptions at CVS—or charges you more for using a different pharmacy—that's called "steering." It's legal in most states, even though it limits your choices.

According to the American Medical Association, 72% of Americans are covered by health insurers with their own PBMs. (Source: AMA, 2024)

Three-quarters of Americans have their prescriptions controlled by companies that profit from steering them to their own pharmacies.

CVS-Aetna Market Dominance by Sector

Source: Drug Channels Institute, 2024 PBM Market Analysis; AMA Competition Report 2024

The Bigger Picture: Healthcare Monopolization

The CVS-Aetna merger didn't happen in isolation. It was part of a monopolization wave:

What You Can Do

1. Understand Your Rights

If your insurance forces you to use a specific pharmacy, ask about exceptions. Under most state laws, you have the right to request a network exception if you can demonstrate medical necessity or if the preferred pharmacy is significantly inconvenient.

If you're denied a medication due to prior authorization or formulary restrictions, you have the right to appeal. Many denials are overturned on appeal, but most patients don't bother. Know your rights as a patient.

2. Ask About Cash Prices

Here's something the PBM system doesn't want you to know: sometimes paying cash is cheaper than using your insurance.

Pharmacies like Costco, independent pharmacies, and services like GoodRx often offer prices lower than your insurance copay. This is possible because insurance prices are based on inflated PBM contracts, while cash prices reflect actual market rates.

Always ask: "What's the cash price?" Compare it to your copay. You might be surprised. For more savings strategies, see our guide on how to cut your healthcare costs by $1,200+ per year.

3. Check for Generic Alternatives

If your insurance requires prior authorization or charges a high copay for your medication, ask your doctor about generic alternatives. Many brand-name drugs have generic equivalents that work just as well at a fraction of the cost.

The PBM system often favors brand-name drugs because they generate larger rebates—even when generics would be cheaper for you.

4. File Complaints

If you believe you've been harmed by anti-competitive PBM practices, file complaints with:

• Your state insurance commissioner: They regulate insurance practices in your state
• The FTC: ftc.gov/complaint accepts complaints about anticompetitive behavior
• Your state attorney general: Many state AGs have active investigations into PBM practices
• CMS (if you have Medicare): cms.gov for Medicare-related complaints

If you need help navigating a medical bill dispute, see our complete guide on what to do when you can't afford a medical bill.

5. Support Legislative Reform

Several states have passed or are considering PBM reform legislation:

• Rebate pass-through laws: Require PBMs to pass drug manufacturer rebates to patients
• Spread pricing bans: Prohibit PBMs from keeping the difference between what they charge insurers and pay pharmacies
• Any-willing-pharmacy laws: Prevent PBMs from excluding pharmacies that meet quality standards
• PBM licensure: Require PBMs to register with state regulators and disclose pricing practices

Contact your state legislators and ask where they stand on PBM reform.

The Real Fix

Individual action helps, but it won't solve this. The system is designed to extract profit from patients—and it's working exactly as intended.

Real change requires structural reform:

• Break up the monopolies. Congress can pass antitrust legislation forcing CVS to divest Aetna or Caremark. The FTC can block future healthcare mergers. Pressure your representatives to act.
• Ban PBM conflicts of interest. Prohibit PBMs from owning pharmacies or being owned by insurers. Several states are already considering this.
• Medicare for All. A single-payer system eliminates PBMs entirely. No middlemen, no spread pricing, no steering. Drug prices negotiated directly by the government—like every other developed country.
• Expand Medicare drug negotiation. The Inflation Reduction Act started this for 10 drugs. Push to expand it to all medications.

The CVS-Aetna merger proved that regulators won't protect you from healthcare monopolies. Six years later: FTC investigations, a $290 million fraud verdict, congressional reports exposing anti-competitive tactics, thousands of independent pharmacies gone.

When one company controls whether your prescription is covered, how much you pay, and where you fill it—the incentives are aligned against you.

Don't wait for someone else to fix this. They won't.

If you've experienced steering, denied medications, or surprising pharmacy bills—you're not alone. And you're not powerless. Start by understanding exactly what you're being charged.